title: A pilot study evaluating a new low-volume colon cleansing procedure for capsule colonoscopy.
abstract: OBJECTIVE
  Colon capsule endoscopy (CCE) offers an alternative approach for endoscopic visualization of the colon. Some of the current CCE bowel cleansing regimens use sodium phosphate, which has raised safety concerns. Therefore, the aim of the current study was to test the feasibility and efficacy of a new low-volume, sodium phosphate-free polyethylene glycol (PEG) bowel preparation.
  
  
  METHODS
  The first 26 patients (original cleansing procedure) received a colon cleansing regimen of PEG plus ascorbic acid: patients drank 1 L in the evening and 0.75 L in the morning before capsule ingestion. Patients also drank an additional 0.5 L PEG boost and an optional 0.25 L PEG boost during the capsule procedure. Following an interim analysis, the cleansing procedure of the subsequent 24 patients was modified, with the morning intake before capsule ingestion being increased to 1 L, as well as the second boost (0.25 L) being administered 1 - 2 hours earlier (modified cleansing procedure).
  
  
  RESULTS
  The overall colon cleanliness was considered to be good or excellent in 83 % (original cleansing procedure) and 82 % (modified cleansing procedure) of patients, without any significant difference between regimens (P > 0.05). In 37 /49 (76 %) of the CCE procedures, the hemorrhoidal plexus was identified and thus the examination was considered complete, with no significant differences between the two CCE cleansing procedures. The capsule sensitivity and specificity for detecting colonic polyps ≥ 6 mm were 91 % (95 %CI 70 % - 98 %) and 94 % (95 %CI 87 % - 97 %), respectively, compared with standard optical colonoscopy.
  
  
  CONCLUSIONS
  A colon cleansing procedure using PEG + ascorbic acid for capsule colonoscopy yielded an adequate cleansing level in > 80 % of patients, a completion rate of 76 %, and good accuracy for detecting polyps. This procedure may be considered as an alternative, particularly for patients in whom sodium phosphate-based preparations are contraindicated.
authors.affiliation: Department of Internal Medicine I, Sana Klinikum Lichtenberg, Berlin, Germany. d.hartmann@sana-kl.de
authors.forename: D
authors.initials: D
authors.lastname: Hartmann
authors.forename: M
authors.initials: M
authors.lastname: Keuchel
authors.forename: M
authors.initials: M
authors.lastname: Philipper
authors.forename: I M
authors.initials: IM
authors.lastname: Gralnek
authors.forename: R
authors.initials: R
authors.lastname: Jakobs
authors.forename: F
authors.initials: F
authors.lastname: Hagenmüller
authors.forename: H
authors.initials: H
authors.lastname: Neuhaus
authors.forename: J F
authors.initials: JF
authors.lastname: Riemann
mesh_terms: D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000008:administration & dosage; D053704:Capsule Endoscopy; D002400:Cathartics / Q000008:administration & dosage*; D003111:Colonic Polyps / Q000175:diagnosis*; D003113:Colonoscopy; D004733:Enema / Q000379:methods*; D005260:Female; D005772:Gastrointestinal Transit; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012680:Sensitivity and Specificity
chemical_list: D002400:Cathartics; C520497:MoviPrep; D011092:Polyethylene Glycols; D001205:Ascorbic Acid